U.S. pharmaceutical company Moderna says its new vaccine is nearly 95% effective against COVID-19.
Its first analysis was based on 95 cases of COVID-19, of which 90 received a placebo and 5 received the vaccine.
There were 11 serious cases in the placebo group and none in those who received the vaccine.
The 95 cases included 15 adults aged 65 or older and 20 participants from various communities, including 12 people identified as Hispanic, 4 black Americans, 3 Asian Americans, and 1 multiracial.
The results come a week after Pfizer Inc and its German partner BioNTech SE said their investigational vaccine was over 90% effective based on initial data.
Moderna, which went public in 2018, has received nearly $ 1 billion in research and development funding from the U.S. government and has entered into a deal worth $ 1.5 billion to deliver 100 million doses.
The US government has an option for an additional 400 million doses and Moderna also has supply agreements with other countries.